Compaction of calf thymus DNA (ct-DNA) by two cationic
gemini surfactants,
12-4-12 and 12-8-12, in the absence and presence of negatively charged
SiO2 nanoparticles (NPs) (∼100 nm) has been explored
using various techniques. 12-8-12 having a longer hydrophobic spacer
induces a greater extent of ct-DNA compaction than 12-4-12, which
becomes more efficient with SiO2 NPs. While 50% ct-DNA
compaction in the presence of SiO2 NPs occurs at ∼77
nM of 12-8-12 and ∼130 nM of 12-4-12, but a conventional counterpart
surfactant, DTAB, does it at its concentration as high as ∼7
μM. Time-resolved fluorescence anisotropy measurements show
changes in the rotational dynamics of a fluorescent probe, DAPI, and
helix segments in the condensed DNA. Fluorescence lifetime data and
ethidium bromide exclusion assays reveal the binding sites of surfactants
to ct-DNA. 12-8-12 with SiO2 NPs has shown the highest
cell viability (≥90%) and least cell death in the human embryonic
kidney (HEK) 293 cell lines in contrast to the cell viability of ≤80%
for DTAB. These results show that 12-8-12 with SiO2 NPs
has the highest time and dose-dependent cytotoxicity compared to 12-8-12
and 12-4-12 in the murine breast cancer 4T1 cell line. Fluorescence
microscopy and flow cytometry are performed for in vitro cellular uptake of YOYO-1-labeled ct-DNA with surfactants and SiO2 NPs using 4T1 cells after 3 and 6 h incubations. The in vivo tumor accumulation studies are carried out using
a real-time in vivo imaging system after intravenous
injection of the samples into 4T1 tumor-bearing mice. 12-8-12 with
SiO2 has delivered the highest amount of ct-DNA in cells
and tumors in a time-dependent manner. Thus, the application of a
gemini surfactant with a hydrophobic spacer and SiO2 NPs
in compacting and delivering ct-DNA to the tumor is proven, warranting
its further exploration in nucleic acid therapy for cancer treatment.